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INTRODUCTION: Bladder cancer exhibits a broad spectrum of heterogenous clinical behavior. Conven-
tionally used clinicopathological factors are associated with certain limitations regarding the accurate
prediction of outcome. Recent studies have focused on the predictive role of cellular regulatory markers.
PRESENTATION:Thepresent case aimed todescribe an extremely rare case of non-muscle invasive bladder
cancer (NMIBC) patient with early isolated bone metastases following curative surgery. An assessment
of the alterations of cellular regulatory biomarkers using immunohistochemistry was performed and a
review of previous literatures is presented.
DISCUSSION: It is very unusual feature that the patients with NMIBC who developed bone metastases
without regional lymphnodemetastasis or local invasion. The patient had a solitary, high-grade T1 tumor
which was not associated with carcinoma in situ and microscopic lymphovascular invasion. However, it
had rapidlymetastasized to distant sites following deﬁnitive surgery and exclusively limited to bones. Of
special interest appears that altered expressions of combined cellular biomarkers including p53, Ki-67,
and epidermal growth factor receptor were not observed focally, but rather diffusely and intensively
throughout the tumor tissue.
CONCLUSION: As an accurate prediction of outcome in patient with bladder cancer is currently limited,
individual targeted approach based on pathological biomarkers may be helpful to determining what
treatments are best or when the optimal time is.
© 2015 The Author. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Over 70% of patients with newly diagnosed bladder cancer
have non-muscle invasive bladder cancer (NMIBC). The recur-
rence rate is high (50–70%) and a signiﬁcant proportion (15–20%)
will progress to muscle invasive disease [1]. As these tumors
exhibits unpredictable clinical behavior regarding disease progres-
sion, standard prognostic characteristics are of limited predictive
value for prognosis. Therefore, it is crucial to understand the com-
plex molecular events that may explain the clinical heterogeneity.
Molecular biomarkers have been investigated to improve the pre-
diction of individual outcomes [2]. NMIBC metastasis to distant
organs without local invasion or regional metastasis is a very rare
occurrence. This is a case of unexpected isolated bone metastases
in a patient with NMIBC following curative surgery. We also inves-
tigated the expression of cell cycle regulatory biomarkers, which
has been extensively studied in bladder cancer for prognostication,
and reviewed the related literatures.
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2. Presentation of case
A 60-year-old man presented with intermittent gross
hematuria 1 year ago. A computed tomography (CT) scan of
the abdomen revealed distended bladder with diverticulae
and a 4.5×3.5×4.1 cm-sized bladder mass, approach-
ing the ureterovesical junction (Fig. 1A and B). Severe
hydroureteronephrosis with parenchymal thinning of the affected
kidney was identiﬁed. There was no evidence of lymph node or
distant metastasis. Bone scintigraphy did not show any metastatic
sites (Fig. 1C). The patient has suffered from paraplegia secondary
to spinal infection of unknown origin since young adolescent and
attempted voiding through manually compressing the bladder.
Since the initial transurethral resection (TUR) of the bladder
tumor was incomplete and high-grade T1 urothelial carcinoma
was diagnosed, the patient underwent a second TUR and random
biopsies of the bladder wall and prostate gland. The patholog-
ical examination revealed that the tumor did not invade the
muscularis propria and itwas not associatedwith concomitant car-
cinoma in situ (CIS). As the patient belonged to high-risk group
and the tumor was located at sites difﬁcult to resect completely,
a deﬁnitive extirpative surgery was considered; however, the
patient insisted on a bladder preservation approach. A follow-up
http://dx.doi.org/10.1016/j.ijscr.2015.03.029
2210-2612/© 2015 The Author. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Contrast-enhanced computed tomography (CT scan prior to surgery. (A) The preoperative CT scan shows multiple diverticula in the bladder. (B) Heterogenously
enhancing mass in the bladder (arrows) involving the ureterovesical junction. (C) Bone scintigraphy reveals no lesion exhibiting abnormal uptake. Contrast-enhanced CT
scan following surgery. (D) The postoperative CT reveals a bulky osteoblastic lesion on the left iliac wing (arrowheads). (E) There was no evidence of local or regional relapse
in the surgical ﬁeld. (F) Bone scan shows multiple areas of abnormal uptake along the entire skeleton.
Fig. 2. Pathologic characteristics of specimens obtained following partial cystectomy and iliac bone biopsy. (A) The bladder tumor was diagnosed as non-muscle invasive,
high-grade urothelial carcinoma (H&E, ×200). (B) The iliac bone specimen corresponded to metastatic urothelial carcinoma (H&E, ×200). Immunohistochemistry of the
bladder tumor. (C) The tumor cells exhibits strong and diffuse immunoreactivity for p53 protein (×400). (D) The Ki-67 labeling index was high with 60% positivity (×400).
H&E; hematoxylin-eosin.
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Table 1
Summary of immunohistochemical biomarkers used in the study.
Biomarkers Clinical status No. of patients Results Reference
Combination of p53, p27 and Ki-67 pT1/RC 80 Combination of biomarkers improves the prediction of RFS and CSS. Shariat et al. [6]
Ki-67 All stages/RC 713 High Ki-67 index is inversely associated with RFS and CSS. Margulis et al. [7]
Combination of p53, pRB, p21 and p16 pT1-2/RC 324 The increased number of altered cell cycle regulatory markers
improves the prediction of RFS and CSS.
Shariat et al. [8]
EGFR pT1/TUR 212 EGFR status is independently associated with stage progression and
survival.
Mellon et al. [9]
RC, radical cystectomy; RFS, recurrence-free survival; CSS, cancer-speciﬁc survival; EGFR. epidermal growth factor receptor; TUR, transurethral resection.
CT scan demonstrated no regional or distant metastasis. Laparo-
scopic nephroureterectomy was performed, followed by open
partial cystectomy with bladder cufﬁng and ipsilateral pelvic lym-
phadenectomy. On microscopic examination, the residual tumor
was only identiﬁed around the ureterovesical junction. The tumor
focally inﬁltrated suburothelial connective tissue, without detru-
sor muscle invasion (Fig. 2A). There was no tumor invasion of the
intravesical portion of the distal ureter. Microscopic lymphovascu-
lar invasion was not observed. All the surgical margins were free of
tumor. There was no metastasis in the regional lymph nodes. The
pathologic ﬁndings were the same as those of the TUR specimens.
Postoperatively, the patient was followed up regularly and
remained well for 3 months. Subsequently, the patient devel-
oped generalized malaise. A follow-up CT scan revealed a
5.5×5.0×4.2 cm bulky osteoblastic lesion on the left iliac wing.
There was no local or regional relapse in the previous surgical
ﬁelds (Figs. 1D and E). A bone scan revealed multiple new areas
exhibiting abnormal uptake in the vertebrae, pelvic bone, femoral
head, left iliac bone and proximal metaphysis of femur (Fig. 1F). No
other lesionswere identiﬁedduring further investigation, including
positron emission tomography-CT scan and magnetic resonance
imaging. Ultrasound-guided needle biopsy of a left iliac bone lesion
was performed and the bone lesion was diagnosed as high-grade
urothelial carcinoma, metastatic from the bladder (Fig. 2B).
It has been demonstrated that cellular regulatory markers
improve the accuracy of prediction of clinical outcome in patient
with bladder cancer [2]. Therefore, we investigated the expression
of established cellular markers using immunohistochemistry. Dif-
fuse co-expression of cytokeratin 7 and 20 in the bladder as well
as the bone lesions deﬁnitely identiﬁed primary and metastatic
urothelial carcinoma. The tumor cells exhibited strong and dif-
fuse nuclear positivity for p53 protein (60–70%). The Ki-67 labeling
indexwas also high (50–70%) positivity (Fig. 2C and D). In addition,
the tumor cells were diffusely positive for epidermal growth factor
receptor (EGFR) (data not shown). Of note, therewas high intensity
expression of p53, Ki-67, and EGFR in all the pathology speci-
mens. The patient received combination chemotherapy, including
gemcitabine and cisplatin; however, he developed grade 3, non-
hematologic toxicity. The patient refused further chemotherapy
and succumbed to the disease 4 months later.
3. Discussion
In general, bladder cancer staged Ta, T1, and CIS are collectively
referred to as NMIBC. The prognosis is based on the pathologic
ﬁndings regarding tumor grade,multiplicity, size, concomitant CIS,
depth of invasion, and early recurrence [3–5]. However, these fac-
tors are not adequately accurate in predicting the individual clinical
behavior. Moreover, patients with high-grade, T1 NMIBC should
be aware of their potentially worse prognosis [4,5]. It is impor-
tant to determine whether the bladder may be preserved without
progression or should be removed in a timely manner.
The identiﬁcation of prognostic biomarker in bladder cancer has
progressed over the last few years [2]. Those associated with the
cell cycle and cell proliferation/apoptosis are the most extensively
investigated biomarkers. Of note, the combination of these cel-
lular biomarkers provided more accurate prognostic information
compared to any individual marker [2,6–8]. (Table 1). Therefore,
we assessed whether the tissue expression of established cellular
biomarkers, such as p53 and Ki-67, exhibits meaningful alterations
in the specimens. These biomarkers are well studied prognostica-
tor that were found to be correlated with progression in bladder
cancer [2]. Nuclear p53 immunoreactivity is generally considered
to be altered when the samples show at least 10% nuclear reactiv-
ity [8]. The Ki-67 labeling index is considered high when it is 20%
or greater [7]. All the specimens exhibited p53 and Ki-67 positiv-
ity in more than 50% of the tumor cells. These alterations were not
observed focally, but rather diffusely throughout the tumor tissue.
Additionally, we assessed positivity for EGFR, a receptor tyrosine
kinase of the ErbB family. Overexpression of EGFR was found to be
associated with progression of high-grade T1 bladder cancer and
decreasedcancer-speciﬁc survival [9]. Togetherwithp53andKi-67,
overexpression of EGFR was widely identiﬁed.
This is a case of initially diagnosed NMIBC that developed early,
multiple and isolated bonemetastasis. It is very unusual for patient
with NMIBC to develop bone metastases without regional lymph
node metastasis or local invasion. The patient had a solitary, high-
grade T1 tumor, which was not associated with CIS. In addition,
there was no evidence of microscopic lymphovascular invasion of
residual tumor at the specimens from TURs and partial cystectomy.
However, the disease rapidly spread to distant organs following
surgical excision and was exclusively limited to the bones. It is
unlikely that bone metastasis was caused by direct invasion or
tumor spillage during the operation. First, partial cystectomy with
bladder cufﬁngwas performed using an open technique,with extra
care taken not to contaminate the surgical ﬁled with tumor. Sec-
ond, the residual tumor was only conﬁned to the lamina propria in
the partial cystectomy specimen. Third, there was no evidence of
local recurrence or regional lymph node metastasis on the follow-
up CT scan. Therefore, it appears that the tumor metastasized to
the adjacent iliac bone through the hematogenous route and then
extensively spread to other distant bones.
It is reasonable to assume to hypothesize that long-standing,
high-grade T1 tumor with extensive alterations of cellular regu-
lating markers may be considered as aggressive disease, even in
patients without muscle invasion. In addition, partial cystectomy
may offer control of localized invasive bladder cancer in patients
with a unifocal tumor that can be safely resected. However, about
20% of patients develop recurrence with locally advanced diseases
or distant metastasis [10]. Although the high-grade, T1 tumors are
suitable candidate for partial cystectomy, patients with marked
alterations of combined biomarker expressionmay be beneﬁtmore
from immediate cystectomy.
4. Conclusion
The therapeutic options for T1 NMIBC patients with high-grade
tumors are currently limited. Personalized targeted therapy based
on pathological biomarkers may prove to be helpful in determin-
ing the optimal treatment and timing. Therefore, earlier aggressive
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and comprehensive systemic therapy, along with deﬁnitive local
therapy is recommended for NMIBC patients with a high risk of
progression or metastasis.
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